... with treatment outcomes of various human malignancies, including lung cancer. However, the clinical implications of this protein in surgically resected lung cancers harboring epidermal growth factor receptor (EGFR) mutations have not been investigated. Methods: Data were collected from patients who underwent...

...Yuki Akazawa; Satoshi Igawa; Kaori Yamada; Hiroki Yamamoto; Yuri Yagami; Nobuki Kaizuka; Hiroya Manaka; Masashi Kasajima; Yoshiro Nakahara; Takashi Sato; Hisashi Mitsufuji; Masanori Yokoba; Masaru Kubota; Jiichiro Sasaki; Katsuhiko Naoki Introduction: Epidermal growth factor receptor (EGFR...

...Jeng-Sen Tseng; Kuo-Hsuan Hsu; Zhe-Rong Zheng; Tsung-Ying Yang; Kun-Chieh Chen; Yen-Hsiang Huang; Kang-Yi Su; Sung-Liang Yu; Gee-Chen Chang Objectives: The characteristics and efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in advanced EGFR -mutant lung...

... of surgery or irradiation may benefit from systemic therapies. Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blockers (ICBs) showed activity in R/M sSCC. In this study, we aimed at exploring the possible role of PD-L1 expression in predicting response to anti-EGFR...

...Sook-Hee Hong; Ho jung An; Kihyun Kim; Seung Sei Lee; Yun-Gyoo Lee; Young-Jin Yuh; I Cheon Park; Yee Soo Chae; Tae-Won Jang; Jin-Hyoung Kang Objectives: Anti-angiogenic agents are reported to exert clinical activity on epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancers. We...

.... Knockdown of TDO2 expression also induced inactivation of the epidermal growth factor receptor signaling pathway. Conclusion: Our results imply that TDO2 could play an important role in the progression of ESCC. Furthermore, TDO2 may be a potential therapeutic target in ESCC. Cancer stem cells (CSCs) have...

...Katsuhiro Masago; Kei Irie; Shiro Fujita; Fumiko Imamichi; Yutaka Okada; Nobuyuki Katakami; Shoji Fukushima; Yasushi Yatabe Purpose: The purpose of the study was to evaluate the site of paronychia in patients with non-small cell lung cancer harboring an epidermal growth factor receptor (EGFR) gene...

... of childhood cancer probably arising from stem mesenchymal or neural crest cells. The epidermal growth factor receptor (EGFR) acts as a driver oncogene in many types of solid tumors. However, its involvement in ES remains poorly understood. Methods: Human SK-ES-1 and RD-ES ES cells were treated with EGF...

... a poor prognosis (p = 0.032). Conclusions: The Q787Q EGFR polymorphism allows stratifying lung squamous cell carcinoma patients and could be an independent prognostic marker, particularly among those in stages I and II. [email protected] Polymorphism Epidermal growth factor receptor...

...Satoshi Igawa; Masashi Kasajima; Mikiko Ishihara; Michiko Kimura; Yasuhiro Hiyoshi; Maiko Asakuma; Sakiko Otani; Ken Katono; Jiichiro Sasaki; Noriyuki Masuda Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor receptor (EGFR) are the most commonly encountered EGFR...

... of response to anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapy by patients with metastatic colorectal cancer (mCRC). However, it has been based on the study of mainly Caucasian mCRC patients. This prospective study investigated the relationship between the mutation status of EGFR...

...Soichi Oka; Hidetaka Uramoto; Hidehiko Shimokawa; Sohsuke Yamada; Fumihiro Tanaka The overexpression of Arf6 and GEP100 is responsible for the invasive activity that is crucial for the activation of the epidermal growth factor receptor (EGFR) signaling pathways in human cancer. However, whether...

...Jun Fukihara; Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Toshiaki Matsuda; Toshiki Yokoyama; Yoshinori Hasegawa Background: The presence of EGFR (epidermal growth factor receptor) mutations is a robust predictor of EGFR tyrosine kinase inhibitor (TKI...

... retreated with the same agent(s), 1 with a different agent possessing the same mechanism of action (e.g., in case of an epidermal growth factor receptor inhibitor, using gefitinib first, then erlotinib), and 5 with the same agent(s) in combination with other agents. Conclusion: Our pilot data suggest...

...Domenico Cante; Maria Rosa La Porta; Pierfrancesco Franco; Piera Sciacero; Giuseppe Franco Girelli; Annamaria Marra; Gianmauro Numico; Nerina Denaro; Elvio Grazioso Russi; Umberto Ricardi It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances...

... 1-year survival was 29% (95% CI: 11-51%), 5 patients lived >12 months. Treatment-related toxicities of grade 3-4 occurred in 5 patients. Patients with epidermal growth factor receptor amplification and never smokers had the longest OS (22.3 and 16.6 months, respectively). Conclusions: Erlotinib...

.... Doxorubicin Breast cancer Estrogen Estrogen receptor Epidermal growth factor receptor National Institutes of Health (NIH) 10.13039/100000002 Breast cancer is the most commonly diagnosed and the second most deadly cancer in women [ 1 ]. Clinically, breast tumors can be classified...

...) and to investigate possible associations of NSCLC with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutations. Methods: Patients with stage IV NSCLC were screened for EML4-ALK rearrangement and EGFR mutations at the Peking...

...Joshua Peck; Lai Wei; Mark Zalupski; Bert O’Neil; Miguel Villalona Calero; Tanios Bekaii-Saab Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial...

...Robert Königsberg; Wolfgang Hulla; Martin Klimpfinger; Angelika Reiner-Concin; Tanja Steininger; Wilfried Büchler; Robert Terkola; Christian Dittrich Treatment of metastasized colorectal cancer (mCRC) patients with anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibodies...